Health Topic


Cardiac Biomarker Solutions from Roche

In cardiovascular disease (CVD) management, early detection and timely initiation of appropriate treatment are crucial. As a market leader in cardiac biomarkers, Roche is committed to continuing cardiology research to advance early diagnosis and help improve clinical decisions.


Heart Failure

NT-proBNP is a well-established Heart Failure (HF) biomarker that can accurately provide objective information to support clinical decision-making from diagnosis to monitoring, to deliver improved care for every HF patient.  

NT-proBNP is recognised as the Gold Standard HF biomarker because it is a powerful prognosticator regardless of therapy.1

Learn More


Atrial Fibrillation

GDF-15 is the strongest predictor in the ABC bleeding risk score, providing an improved understanding of each patient’s bleeding-risk profile which may help to inform treatment decisions.2

Learn More


Acute Coronary Syndrome

cTnT-hs is a highly sensitive test that allows for earlier detection of acute myocardial infarction (AMI), facilitating faster triaging for earlier initiation of appropriate therapy.3-5

A joint approach with Troponin T detection at the Point-of-Care can help achieve faster triaging of patients with suspected acute myocardial infarction in pre-hospital care and the emergency room.6-7


Atherosclerotic Cardiovascular Disease (ASCVD)

Elevated lipoprotein(a) [Lp(a)] is an inherited and causal risk factor for ASCVD.  Testing for elevated Lp(a) is recommended in all patients with premature ASCVD and those considered to be at intermediate-to-high risk of ASCVD8.  

Learn More

Ben Smith

Cardiology  Disease Area Lead

Benjamin Smith BCom, MBA


Ben is the Cardiology Disease Area Lead for Roche Diagnostics Australia. Ben has been with Roche for over 7 years in the Cardiac and Critical Care space. His experience as International Product Manager in Switzerland has paved the way for him to return to his home country, taking on the role of Cardiology Disease Area Lead - educating his colleagues and customers alike in the value of cardiac biomarkers for cardiovascular disease.



Get in touch to find out more about our Cardiac Solutions

This page is provided as a contact service and does not replace the advice of a physician. Roche cannot respond to questions about general medical information or questions regarding your personal medical condition. Medications and diagnostics products can not be directly ordered through this website. Please note that we do not respond to form letters or e-mail campaigns.

Form Successfully Submitted!
Thank you for your submission!


  1. McKie and Burnett (2016). J Am Coll Cardiol. 68, 2437-2439
  2. Hijazi et al. (2016). Lancet. 387, 2302-2311
  3. Bandstein et al. (2014). J Am Coll Cardiol. 63, 2569-78
  4. Body et al. (2015). Clin Chem. 61, 983-939
  5. Rubini-Giménez et al. (2013). Int J Cardiol. 168, 3896-3901
  6. Roche CARDIAC POC Troponin T- Method Sheet-package insert 
  7. Stengaard et al. (2013). Am J Cardiol. 112, 1361-1366
  8. B. G. Nordestgaard and A. Langsted, "Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology," Journal of Lipid Research, vol. 57, no. 11, pp. 1953-1975, 2016, doi: 10.1194/jlr.R071233. 


NT-proBNP: N-terminal prohormone of brain natriuretic peptide; POC: point of care